Fig. 5

The effect of osimertinib on CTC15063_{EGFR L858R, T790M} xenografts tumor inhibition or tumor re-development due to osimertinib resistance. a CTC15063_{EGFR L858R, T790M} xenograft growth curves for female nu/nu mice (mean ± SEM, n = 6) treated with 50 mg/kg erlotinib or vehicle control for 35 days. b CTC15063_{EGFR L858R, T790M} xenograft growth curves for female nu/nu mice (mean ± SEM, n = 6) treated with 5 mg/kg osimertinib or vehicle for 24 days. c CTC15063_{EGFR L858R, T790M} xenograft growth curves of six female nu/nu mice (osimertinib 1–6) treated with 5 mg/kg osimertinib for 95 days. d Secondary CTC15063_{EGFR L858R} xenografts derived from osimertinib-3 under 5 mg/kg osimertinib or vehicle control treatments for 21 days (mean ± SEM, n = 6). e Frequencies of the EGFR L858R and T790M mutations in the tumor biopsy from patient CTC15063_{EGFR L858R, T790M} (85.6% and 71.6%, respectively) were similar to those in the initial CTC15063_{EGFR L858R, T790M} xenograft tumors (83.3% and 77.6%, respectively), but were higher than those in osimertinib-3-derived secondary xenografts (53.6% and 41.7%, respectively); f 33 novel secondary mutations were identified in osimertinib-3-derived xenografts, including BRAF (G7V) (11.54%) and PIK3C2A (A86fs) (13.64%)